Helmholtz Zentrum München

News and Video Search Results

News coverage

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

GlobeNewswire 23 Apr 2024

*A Novel Therapeutic Approach to Treatment using ITM-31**Garching/Munich, Munich and Münster, **April 23, 2024 – *The..

Climate Change Disrupts Vital Ecosystems In The Alps
Eurasia Review 24 Mar 2024
Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA
PR Newswire Asia 26 Oct 2023
Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023
PR Newswire Asia 18 Sep 2023
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors
PR Newswire Asia 11 Sep 2023

0 shares 1 views

You might like

Helmholtz Zentrum München media coverage

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

PR Newswire Asia 29 Jun 2023

New state-of-the-art facility to develop immunotherapy assets to address unmet needs in cancer treatment

SINGAPORE, June..

Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer

Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer

PR Newswire Asia

06 Jun 2023

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

PR Newswire Asia

18 Apr 2023

Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types
GlobeNewswire 23 Aug 2023
Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singaporeimage_1.png
Media OutReach 28 Jun 2023

Advertisement

More coverage

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

PR Newswire Asia 11 Apr 2023

GUANGZHOU, China, April 11, 2023 /PRNewswire/ -- April 7^th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted IND..

PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy

PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy

PR Newswire Asia

29 Mar 2023

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

PR Newswire Asia

17 Feb 2023

Annual General Meeting of HUBER+SUHNER AG: Shareholders endorse all of the Board of Directors’ proposals
EQS Group 29 Mar 2023
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
GlobeNewswire 13 Mar 2023